Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Disorders of Hemostasis01:24

Disorders of Hemostasis

676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676
X-linked Traits01:19

X-linked Traits

53.0K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Introduction to Hemostasis01:05

Introduction to Hemostasis

4.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.9K
Rh Blood Group01:19

Rh Blood Group

1.3K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

4.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica.

Research and practice in thrombosis and haemostasis·2026
Same author

Natural History of Fetal Non-Nuchal Lymphatic Malformations: A Single Center Retrospective Study.

Prenatal diagnosis·2026
Same author

Treatment preferences of people with hemophilia and caregivers: a plain language summary.

Therapeutic advances in hematology·2026
Same author

Antiphospholipid syndrome in the paediatric population: performance of ACR-EULAR classification criteria in a controlled cohort.

Lupus science & medicine·2026
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026

Video Experimental Relacionado

Updated: May 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K

La hemofilia

Pratima Chowdary1, Manuel Carcao2, Gili Kenet3

  • 1Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK; Department of Haematology, Cancer Institute, University College London, London, UK.

Lancet (London, England)
|March 1, 2025
PubMed
Resumen

La hemofilia A y B son trastornos sanguíneos hereditarios. Los tratamientos modernos, incluida la sustitución de factores, las terapias no sustitutivas y la terapia génica, mejoran significativamente la calidad de vida del paciente y reducen las complicaciones.

Más Videos Relacionados

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.2K

Videos de Experimentos Relacionados

Last Updated: May 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.2K

Área de la Ciencia:

  • Hematología
  • La genética
  • Farmacología

Sus antecedentes:

  • Trastornos sanguíneos congénitos ligados al X causados por deficiencias en los factores de coagulación VIII (hemofilia A) y IX (hemofilia B).
  • La deficiencia grave (< 1% de actividad del factor) conduce a hemorragias espontáneas en la primera infancia; las formas moderadas/ leves se presentan con hemorragias después de un trauma o cirugía.
  • El diagnóstico precoz a través de un alto índice de sospecha y la medición de la actividad de los factores es crucial.

Objetivo del estudio:

  • Revisar las estrategias actuales y emergentes de tratamiento de la hemofilia A y B.
  • Para resaltar el impacto de los avances terapéuticos en los resultados de los pacientes.
  • Para enfatizar la importancia de un cuidado personalizado y de por vida.

Principales métodos:

  • Revisión de la literatura actual sobre el tratamiento de la hemofilia.
  • Análisis de las diferentes modalidades de tratamiento: sustitución de factores, terapias no sustitutivas y terapia génica.
  • Discusión de las estrategias de seguimiento de los tratamientos profilácticos.

Principales resultados:

  • Los avances terapéuticos han mejorado significativamente la mortalidad y la morbilidad en la hemofilia.
  • Varias opciones de tratamiento ofrecen diferentes beneficios con respecto a la profilaxis, el tratamiento a pedido, la administración y los perfiles de efectos secundarios.
  • La gestión personalizada, los equipos multidisciplinarios y la educación del paciente son clave para obtener resultados óptimos.

Conclusiones:

  • La atención integral y las opciones de tratamiento en evolución mejoran la calidad de vida de las personas con hemofilia.
  • Las estrategias de gestión personalizadas y de por vida son esenciales para maximizar el potencial del paciente y minimizar la carga de la enfermedad.
  • La investigación y la educación continuas son vitales para avanzar en el tratamiento de la hemofilia.